KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Non-Current Assets (2017 - 2025)

Aquestive Therapeutics (AQST) has 7 years of Other Non-Current Assets data on record, last reported at $4.2 million in Q4 2024.

  • For Q4 2024, Other Non-Current Assets fell 22.34% year-over-year to $4.2 million; the TTM value through Dec 2024 reached $4.2 million, down 22.34%, while the annual FY2024 figure was $4.2 million, 22.34% down from the prior year.
  • Other Non-Current Assets reached $4.2 million in Q4 2024 per AQST's latest filing, down from $5.4 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $7.8 million in Q4 2020 and bottomed at $4.2 million in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $6.2 million, with a median of $6.5 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: surged 2639.86% in 2020, then decreased 22.34% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $7.8 million in 2020, then fell by 0.01% to $7.8 million in 2021, then dropped by 17.66% to $6.5 million in 2022, then fell by 15.7% to $5.4 million in 2023, then dropped by 22.34% to $4.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $4.2 million in Q4 2024, $5.4 million in Q4 2023, and $5.5 million in Q3 2023.